{"id":"NCT04819776","sponsor":"Vanda Pharmaceuticals","briefTitle":"Evaluation of Efficacy and Safety of Iloperidone in the Acute Treatment of Manic or Mixed Episodes Associated With Bipolar I Disorder","officialTitle":"A Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Iloperidone for 4 Weeks in the Treatment of Patients With Acute Manic Episodes Associated With Bipolar I Disorder","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2021-03-22","primaryCompletion":"2022-09-07","completion":"2023-08-16","firstPosted":"2021-03-29","resultsPosted":"2024-04-16","lastUpdate":"2024-04-18"},"enrollment":417,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Bipolar I Disorder"],"interventions":[{"type":"DRUG","name":"Iloperidone","otherNames":["FANAPTÂ®","VYV-683"]},{"type":"DRUG","name":"Iloperidone Placebo","otherNames":[]}],"arms":[{"label":"Iloperidone","type":"EXPERIMENTAL"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"The aim of this study is to investigate the efficacy, safety, and tolerability of iloperidone compared with placebo in treating acute manic or mixed episodes associated with Bipolar I Disorder.","primaryOutcome":{"measure":"Change From Baseline to Week 4 in Young Mania Rating Scale (YMRS) Total Score","timeFrame":"Week 4","effectByArm":[{"arm":"Iloperidone","deltaMin":-14,"sd":0.64},{"arm":"Placebo","deltaMin":-10,"sd":0.63}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":3,"exclusionCount":2},"locations":{"siteCount":27,"countries":["United States","Bulgaria","Poland"]},"refs":{"pmids":["38236020"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":4,"n":206},"commonTop":["Tachycardia","Dizziness","Dry mouth","Alanine aminotransferase increased","Nasal congestion"]}}